Ohgaki, H. & Kleihues, P. Epidemiology and etiology of gliomas. Acta Neuropathol. 109, 93–108 (2005).

Article  PubMed  Google Scholar 

McLendon, R. et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).

Article  CAS  Google Scholar 

Broekman, M. L. et al. Multidimensional communication in the microenvirons of glioblastoma. Nat. Rev. Neurol. 14, 482–495 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Roesch, S., Rapp, C., Dettling, S. & Herold-Mende, C. When immune cells turn bad — tumor-associated microglia/macrophages in glioma. Int. J. Mol. Sci. 19, 436 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009).

Article  CAS  PubMed  Google Scholar 

Galanis, E. et al. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J. Neurosurg. 89, 425–430 (1998).

Article  CAS  PubMed  Google Scholar 

Johann, P., Lenz, D. & Ries, M. The drug development pipeline for glioblastoma — a cross sectional assessment of the FDA Orphan Drug Product designation database. PLoS ONE 16, e0252924 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nozhat, Z. et al. Advanced biomaterials for human glioblastoma multiforme (GBM) drug delivery. Biomater. Sci. 11, 4094–4131 (2023).

Article  CAS  PubMed  Google Scholar 

Weller, M. et al. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat. Rev. Neurol. 13, 363–374 (2017).

Article  CAS  PubMed  Google Scholar 

Kong, Z., Wang, Y. & Ma, W. Vaccination in the immunotherapy of glioblastoma. Hum. Vaccines Immunother. 14, 255–268 (2018).

Article  Google Scholar 

Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234–239 (2019).

Article  CAS  PubMed  Google Scholar 

Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240–245 (2019).

Article  CAS  PubMed  Google Scholar 

Jackson, C. M., Choi, J. & Lim, M. Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat. Immun. 20, 1100–1109 (2019).

Article  CAS  Google Scholar 

Buckland, B. C. The process development challenge for a new vaccine. Nat. Med. 11, S16–S19 (2005).

Article  CAS  PubMed  Google Scholar 

Ulmer, J. B., Valley, U. & Rappuoli, R. Vaccine manufacturing: challenges and solutions. Nat. Biotechnol. 24, 1377–1383, (2006).

Article  CAS  PubMed  Google Scholar 

Kocarnik, J. M. et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 8, 420–444 (2022).

Article  PubMed  Google Scholar 

The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Oncol. 23, 27–52, (2022).

Bagley, S. J. et al. Glioblastoma clinical trials: current landscape and opportunities for improvement. Clin. Cancer Res. 28, 594–602 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Belykh, E. et al. Blood-brain barrier, blood-brain tumor barrier, and fluorescence-guided neurosurgical oncology: delivering optical labels to brain tumors. Front. Oncol. 10, 739 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Yin, Y. et al. In situ transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy. Nano Lett. 21, 2224–2231 (2021).

Article  CAS  PubMed  Google Scholar 

Conniot, J. et al. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nat. Nanotechnol. 14, 891–901 (2019).

Article  CAS  PubMed  Google Scholar 

Bergquist, B., Mahaley, M. S., Steinbok, P. & Dudka, L. F. Treatment of a brain tumor with BCG cell wall preparation. Surg. Neurol. 13, 197–201 (1980).

CAS  PubMed  Google Scholar 

Mahaley, M. S. et al. Immunobiology of primary intracranial tumors. Part 7: active immunization of patients with anaplastic human glioma cells: a pilot study. J. Neurosurg. 59, 201–207 (1983).

Article  PubMed  Google Scholar 

Agnihotri, S., Yang, K., Mitchell, D. A. & Rich, J. N. A vaccine for glioma. Nat. Cancer 2, 584–586 (2021).

Article  CAS  PubMed  Google Scholar 

Abd-Aziz, N. & Poh, C. L. Development of peptide-based vaccines for cancer. J. Oncol. 2022, 9749363 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Mahdavi, A. & Monk, B. J. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist 10, 528–538, (2005).

Article  CAS  PubMed  Google Scholar 

Brun, S. N. et al. Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma. Oncogene 34, 3770–3779 (2015).

Article  CAS  PubMed  Google Scholar 

Fenstermaker, R. A. et al. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol. Immunother. 65, 1339–1352 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mazur, J., Roy, K. & Kanwar, J. R. Recent advances in nanomedicine and survivin targeting in brain cancers. Nanomedicine 13, 105–137 (2018).

Article  CAS  PubMed  Google Scholar 

Swartz, A. M., Batich, K. A., Fecci, P. E. & Sampson, J. H. Peptide vaccines for the treatment of glioblastoma. J. Neurooncol. 123, 433–440 (2015).

Article  CAS  PubMed  Google Scholar 

Purcell, A. W., McCluskey, J. & Rossjohn, J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 6, 404–414, (2007).

Article  CAS  PubMed  Google Scholar 

Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A. & Moon, J. J. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat. Mat. 16, 489–496 (2017).

Article  CAS  Google Scholar 

Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).

Article  CAS  PubMed  Google Scholar 

Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Waele, J. et al. A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy. J. Exp. Clin. Cancer Res. 40, 213 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Blass, E. & Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215–229 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Lee-Chang, C. & Lesniak, M. S. Next-generation antigen-presenting cell immune therapeutics for gliomas. J. Clin. Invest. 133, e163449 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Datsi, A. & Sorg, R. V. Dendritic cell vaccination of glioblastoma: road to success or dead end. Front. Immunol. 12, 770390 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin, M. J. et al. Cancer vaccines: the next immunotherapy frontier. Nat. Cancer 3, 911–926 (2022).